Response of canine thyroid carcinomas to radioiodine

xlomafota13 shared this article with you from Inoreader Response of canine thyroid carcinomas to radioiodine Via radioactive iodine Vet Comp Oncol. 2021 Sep 2. doi: 10.1111/vco.12770. Online ahead of print. ABSTRACT Radioactive iodine (131 I) has previously been reported to prolong survival in dogs with thyroid carcinoma. This study aimed to describe tumour response and progression-free interval (PFI) in dogs with thyroid carcinomas treated with 131 I. Secondary aims were to describe overall survival time (OST) and prognostic factors. A bi-institutional retrospective review of records iden tified 66 dogs with thyroid carcinoma treated with 131 I from January 2010-April 2020. Response was described using RECIST, or a subjective response assessment where specific tumour measurements were not available. Forty-eight dogs (72.7%) were treatment-naïve and 18 dogs (27.3%) had received prior therapy at the time of 131 I treatment. Objective responses were available for 34 dogs and subjective responses for 58 dogs. The overall response rate (ORR) was 35.3% (4 complete and 8 partial responses). Improvement of clinical signs was seen in 76.2% of dogs (32/42). Kaplan-Meier-estimated median PFI (95%CI) was 301 (217-578) days and OST (95%CI) was 564 (421-865) days. Prior therapy was associated with a lower hazard for progression (HR 0.260 95%CI 0.123-0.548, P=0.0004). Treatment of thyroid carcinoma using 131 I can effectively alleviate clinical signs and reduce disease burden in a proportion of dogs. This article is protected by copyright. All righ ts reserved. PMID:34476889 | DOI:10.1111/vco.12770 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.